Navigation Links
Anterios, Inc. CEO And Founder, Jon Edelson, To Present At Needham & Company's 12th Annual Healthcare Conference
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today that CEO and Founder, Jon Edelson , MD will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. Dr. Edelson will be joining a roster of presenters that includes senior management from some of the most well respected public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors.

"I'm looking forward to presenting at Needham's Annual Healthcare Conference and sharing with the investment community the latest company news from Anterios," stated Dr. Edelson.  "We are at an important phase of our clinical development with ANT-1207, our topical botulinum prescription product.  ANT-1207 has true potential for expanding the aesthetic and medical dermatology marketplace."

About ANT-1207
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.

ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.  

ANT-1207 has been studied for the indications of lateral canthal lines (Crow's Feet wrinkles), hyperhidrosis and acne in multi-center, double-blind, randomized, controlled, dose-escalation studies enrolling approximately 250 subjects. These studies demonstrated that ANT-1207 was well tolerated and demonstrated clinically and statistically significant efficacy versus controls. The Company is currently conducting Phase 2b clinical trials on ANT-1207.

About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com.


'/>"/>
SOURCE Anterios, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cempra to Present Data on Solithromycins (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
5. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
6. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
7. Lexicon To Present At The Needham Healthcare Conference
8. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
9. KaloBios to Present at Needham Healthcare Conference
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. MEI Pharma CEO To Present At Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):